50.10
price down icon0.24%   -0.0757
 
loading
Precedente Chiudi:
$50.18
Aprire:
$50.29
Volume 24 ore:
337.48K
Relative Volume:
0.16
Capitalizzazione di mercato:
$6.07B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-11.82
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
+0.06%
1M Prestazione:
+9.32%
6M Prestazione:
+48.28%
1 anno Prestazione:
+76.20%
Intervallo 1D:
Value
$49.25
$50.91
Intervallo di 1 settimana:
Value
$49.25
$53.42
Portata 52W:
Value
$20.14
$53.42

Guardant Health Inc Stock (GH) Company Profile

Name
Nome
Guardant Health Inc
Name
Telefono
855-698-8887
Name
Indirizzo
3100 HANOVER STREET, PALO ALTO
Name
Dipendente
2,021
Name
Cinguettio
@guardanthealth
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
GH's Discussions on Twitter

Confronta GH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Diagnostics & Research icon
GH
Guardant Health Inc
50.10 6.07B 692.26M -512.41M -274.36M -4.24
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
427.50 156.49B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
203.08 145.01B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
544.17 42.30B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
121.34 34.24B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
164.85 27.64B 15.50B 1.33B 2.16B 7.34

Guardant Health Inc Stock (GH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-10 Iniziato Mizuho Outperform
2025-01-23 Iniziato Barclays Overweight
2024-06-28 Aggiornamento Guggenheim Neutral → Buy
2024-06-03 Ripresa Jefferies Buy
2024-04-24 Ripresa Craig Hallum Buy
2023-12-14 Iniziato Guggenheim Neutral
2023-12-13 Iniziato Wolfe Research Peer Perform
2023-11-13 Aggiornamento Raymond James Mkt Perform → Outperform
2023-09-28 Iniziato Bernstein Outperform
2023-09-27 Aggiornamento Piper Sandler Neutral → Overweight
2023-07-05 Ripresa JP Morgan Overweight
2023-05-26 Aggiornamento Citigroup Neutral → Buy
2023-05-05 Iniziato UBS Buy
2023-03-09 Downgrade Citigroup Buy → Neutral
2023-01-05 Iniziato Scotiabank Sector Outperform
2022-11-01 Downgrade Piper Sandler Overweight → Neutral
2022-10-19 Iniziato Craig Hallum Buy
2022-10-06 Iniziato Stephens Overweight
2022-08-25 Iniziato Credit Suisse Outperform
2022-06-03 Iniziato Piper Sandler Overweight
2022-04-28 Ripresa BTIG Research Buy
2022-02-24 Reiterato Canaccord Genuity Buy
2022-02-24 Reiterato Citigroup Buy
2022-02-24 Reiterato Cowen Outperform
2022-02-24 Reiterato Morgan Stanley Overweight
2022-02-24 Reiterato SVB Leerink Outperform
2022-02-24 Reiterato Stifel Buy
2022-02-24 Reiterato Wells Fargo Overweight
2021-10-15 Ripresa Cowen Outperform
2021-06-15 Iniziato Raymond James Mkt Perform
2021-06-03 Iniziato Goldman Buy
2021-05-25 Iniziato Wells Fargo Overweight
2021-01-11 Iniziato Stifel Buy
2020-09-09 Iniziato Morgan Stanley Overweight
2020-06-12 Iniziato BTIG Research Buy
2020-02-21 Iniziato Guggenheim Buy
2020-01-07 Iniziato Citigroup Buy
2019-08-07 Reiterato Canaccord Genuity Buy
2019-04-16 Iniziato Canaccord Genuity Buy
2019-04-10 Aggiornamento BofA/Merrill Neutral → Buy
2019-02-28 Reiterato BofA/Merrill Neutral
2018-10-29 Iniziato BofA/Merrill Neutral
2018-10-29 Iniziato JP Morgan Overweight
2018-10-29 Iniziato William Blair Outperform
Mostra tutto

Guardant Health Inc Borsa (GH) Ultime notizie

pulisher
Jun 18, 2025

Guardant Health’s Multi-Cancer Detection Test Wins FDA Breakthrough Designation - Medical Product Outsourcing

Jun 18, 2025
pulisher
Jun 17, 2025

Australian biotech uncovers broader view of tumour genetics with liquid biopsy - Mugglehead Magazine

Jun 17, 2025
pulisher
Jun 16, 2025

Insider Sell: Meghan Joyce Sells Shares of Guardant Health Inc (GH) - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health director sells shares worth $157,573 - Investing.com

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health Executives Sell Shares - TradingView

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health up 4% on Q1 beats, 2025 guidance revenue raise - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health (NASDAQ:GH) Given New $65.00 Price Target at Mizuho - MarketBeat

Jun 16, 2025
pulisher
Jun 14, 2025

(GH) Investment Report - news.stocktradersdaily.com

Jun 14, 2025
pulisher
Jun 13, 2025

Mizuho raises Guardant Health price target on positive Shield test outlook - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Guardant Health (GH) Price Target Raised to $65 by Mizuho | GH S - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.

Jun 12, 2025
pulisher
Jun 12, 2025

Guardant Health, Inc. (NASDAQ:GH) Receives $53.29 Consensus PT from Analysts - MarketBeat

Jun 12, 2025
pulisher
Jun 10, 2025

Guardant Health Wins Fast Company's 2025 World Changing Ideas Aw - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening | GH Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility - The ASCO Post

Jun 10, 2025
pulisher
Jun 10, 2025

Insider Sell: Amirali Talasaz Sells 119,284 Shares of Guardant H - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Guardant Health Inc (GH) Shares Up 4.04% on Jun 9 - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Guardant Health at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Guardant Health, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer - BioSpace

Jun 09, 2025
pulisher
Jun 09, 2025

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer | GH Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 07, 2025

ARK Investment Acquires 99.6K Shares of Guardant Health (GH) | G - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Insider Sell: Kumud Kalia Sells 4,000 Shares of Guardant Health Inc (GH) - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Guardant Health Inc (GH) Shares Up 3.5% on Jun 5 - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Mackenzie Financial Corp Has $230,000 Holdings in Guardant Health, Inc. (NASDAQ:GH) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Guardant Health Shares Climb on FDA Breakthrough Status for Cancer Detection Test - MSN

Jun 06, 2025
pulisher
Jun 05, 2025

Minimal Residual Disease Testing Market Set to Witness - openPR.com

Jun 05, 2025
pulisher
Jun 05, 2025

Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com

Jun 05, 2025
pulisher
Jun 04, 2025

ARK Investment Acquires 99.6K Shares of Guardant Health (GH) | GH Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant By Investing.com - Investing.com UK

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health gets FDA breakthrough device status for cancer detection test - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health’s MCD test earns FDA breakthrough designation - Yahoo

Jun 04, 2025
pulisher
Jun 04, 2025

111 Capital Purchases Shares of 8,303 Guardant Health, Inc. (NASDAQ:GH) - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health’s cancer test earns FDA breakthrough status By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Leerink Partners maintains outperform rating for Guardant Health stock By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

ARK Investment Acquires 173K Shares of Guardant Health (GH) | GH Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Stock Surges on FDA Breakthrough Designatio - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Why Guardant Health Stock Surged Nearly 9% Higher Today - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

NCCN Adds 2 Tests to CRC Screening Guidelines - OncLive

Jun 03, 2025
pulisher
Jun 03, 2025

Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?Guardant Health (NASDAQ:GH) - Benzinga

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health shares rise following FDA breakthrough designation By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health shares rise following FDA breakthrough designation - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Gains as FDA Grants Breakthrough Designatio - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health's Shield Multi-Cancer Test Receives FDA Breakthrough Device Designation - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health’s cancer test earns FDA breakthrough status - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Receives FDA Breakthrough Designation for Cancer Detection Test | GH Stock News - GuruFocus

Jun 03, 2025

Guardant Health Inc Azioni (GH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Guardant Health Inc Azioni (GH) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
POTTER MYRTLE S
Director
Jun 18 '25
Sale
49.47
26
1,286
18,154
CLARK IAN T
Director
Jun 17 '25
Sale
48.38
6,672
322,819
9,851
diagnostics_research DGX
$176.50
price down icon 0.06%
diagnostics_research WAT
$351.33
price down icon 0.21%
diagnostics_research LH
$261.38
price up icon 0.70%
$162.28
price up icon 0.66%
diagnostics_research MTD
$1,205.15
price up icon 2.26%
diagnostics_research IQV
$165.59
price up icon 0.76%
Capitalizzazione:     |  Volume (24 ore):